15Feb/13

Medicamento Rituximab es más efectivo que terapia estándar en Linfoma – Comunicado-Prensa.com (Comunicado de prensa)

February 15, 2013Monoclonal Anti-CD20 Antibodiesadmin

Medicamento Rituximab es más efectivo que terapia estándar en Linfoma
Comunicado-Prensa.com (Comunicado de prensa)
El medicamento Rituximab, de Roche, y la bendamustina son más “eficaces y menos tóxicos” que la terapia estándar R-CHOP en el tratamiento del linfoma no Hodgkin. Así lo asegura un estudio de la Universidad de Giessen (Alemania). El estudio …
Empresas.- El tratamiento del linfoma no Hodgkin indolente con bendamustina y …Europa Press

all 2 news articles »

14Feb/13

Empresas.- El tratamiento del linfoma no Hodgkin indolente con bendamustina y … – Europa Press

February 14, 2013Monoclonal Anti-CD20 Antibodiesadmin

Europa Press

Empresas.- El tratamiento del linfoma no Hodgkin indolente con bendamustina y …
Europa Press
El tratamiento del linfoma no Hodgkin indolente con bendamustina y rituximab es “más eficaz y menos tóxico” que la terapia estándar R-CHOP, tal y como ha asegurado el líder del estudio en Fase III ‘Stil-NHL-01 y miembro de la Universidad de Giessen …
Menos medicamentos, menos toxicidadEl Comercio Digital (Asturias)

all 2 news articles »

14Feb/13

Addition of rituximab to ACVBP extended EFS, PFS – Healio

February 14, 2013Monoclonal Anti-CD20 Antibodiesadmin

HealioAddition of rituximab to ACVBP extended EFS, PFSHealioThe addition of rituximab to doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone extended event-free survival and PFS in patients with early-stage diffuse large B-cell lymphoma,…

14Feb/13

US FDA grants "breakthrough" status for Janssen and Pharmacyclics ibrutinib – The Pharma Letter

February 14, 2013Monoclonal Anti-CD20 Antibodiesadmin

US FDA grants “breakthrough” status for Janssen and Pharmacyclics ibrutinib
The Pharma Letter
A Phase III randomized, multi-center registration trial of ibrutinib as a monotherapy versus temsirolimus in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen, RAY (MCL3001). • A Phase III …

14Feb/13

Theradiag's new biotherapy monitoring kits receive CE mark approval – News-Medical.net

February 14, 2013Monoclonal Anti-CD20 Antibodiesadmin

Theradiag’s new biotherapy monitoring kits receive CE mark approval
News-Medical.net
Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostic and in vitro diagnostics, today announced it has obtained a CE mark for two new biotherapy monitoring kits; Tocilizumab (anti-IL6R) and Rituximab (anti-CD20) that …

and more »

14Feb/13

Theradiag Receives CE Mark Approval for Two New Lisa Tracker Monitoring Kits … – Fort Mills Times

February 14, 2013Monoclonal Anti-CD20 Antibodiesadmin

Theradiag Receives CE Mark Approval for Two New Lisa Tracker Monitoring Kits …Fort Mills TimesTheradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostic and in vitro diagnostics, today announced it has obtained a CE mark for…

13Feb/13

Antiphospholipid Syndrome: Using Anticoagulants Properly – Pharmacy Times

February 13, 2013Monoclonal Anti-CD20 Antibodiesadmin

Antiphospholipid Syndrome: Using Anticoagulants ProperlyPharmacy TimesIntravenous immunoglobulin may be of some benefit and cyclophosphamide is sometimes administered, especially in SLE-associated CAPS.10 Rituximab has shown promise in the treatment of…

13Feb/13

Biotech Focus Tracking the Oncology Pipeline – OncLive

February 13, 2013Monoclonal Anti-CD20 Antibodiesadmin

OncLiveBiotech Focus Tracking the Oncology PipelineOncLiveIn a second study, researchers sought to accelerate response to ibrutinib by pairing the drug with rituximab in 40 patients with CLL/SLL (median age, 65 years) considered high risk. In all, 38 o…

13Feb/13

Pharmacyclics First to Announce Breakthrough Therapy Designation in … – Sacramento Bee

February 13, 2013Monoclonal Anti-CD20 Antibodiesadmin

Pharmacyclics First to Announce Breakthrough Therapy Designation in …Sacramento BeeA Phase II single-arm study of ibrutinib as a monotherapy in patients with MCL who received at least one prior rituximab-containing chemotherapy regimen and who progre…

12Feb/13

Pharmacyclics First to Announce Breakthrough Therapy Designation in … – The Herald | HeraldOnline.com

February 12, 2013Monoclonal Anti-CD20 Antibodiesadmin

Pharmacyclics First to Announce Breakthrough Therapy Designation in …The Herald | HeraldOnline.comA Phase II single-arm study of ibrutinib as a monotherapy in patients with MCL who received at least one prior rituximab-containing chemotherapy regimen…

Category Archives: Monoclonal Anti-CD20 Antibodies